Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Ticker SymbolPRPO
Company namePrecipio Inc
IPO dateJul 18, 2000
CEOMr. Ilan Danieli
Number of employees54
Security typeOrdinary Share
Fiscal year-endJul 18
Address4 Science Park
CityNEW HAVEN
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code06511
Phone12037877888
Websitehttps://www.precipiodx.com/
Ticker SymbolPRPO
IPO dateJul 18, 2000
CEOMr. Ilan Danieli
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data